Plain-English translation of NCT07649928 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new medication called ES502 for people with advanced pancreatic cancer that has specific genetic changes. The study will give participants increasing doses of the medication—starting with a small dose and gradually increasing it—to find the dose that is both safe and works best. Researchers will watch carefully for side effects and how well the treatment fights the cancer.
Pancreatic cancer is very difficult to treat, and many current treatments don't work well for patients with specific genetic mutations. This trial is exploring whether this new treatment might offer hope for people whose cancers have stopped responding to standard therapy or who cannot receive standard treatments.
You likely qualify if…
You likely don't qualify if…
You will visit the study clinic regularly to receive injections of the medication once every four weeks. The study starts with a low dose, and if it is tolerated well, future participants will receive higher doses. At each visit, you will have blood tests and imaging scans to check how your cancer is responding and to monitor for any side effects. The trial will take several months or longer depending on how your cancer responds and how you tolerate the treatment.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
China